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Background: Prior Influenza A viral (IAV) infection has been shown to increase
susceptibility to tuberculosis (TB) and TB has also been shown to be a primary cause of
death during pandemics, including the Spanish Influenza outbreak of 1918–1919. The
majority of data has been obtained from mouse models, thus the aim of this study was
to determine the impact of Flu co-infection on host immunity and disease severity in TB
patients at diagnosis.
Methods: Sputum from 282 patients with active TB were analyzed for presence of
FluA/FluB RNA at presentation using multiplex PCR. Sputum RNA was also analyzed
for Mycobacterium tuberculosis (Mtb) load using 16S RNA amplification. Supernatants
from digested sputum and Mtb antigen-stimulated whole blood were analyzed using
multiplex cytokine arrays and PBMC were analyzed for cytokine production from CD4+
T, CD8+ T and Mucosal Associated Invariant T cells (MAITs).
Results: 12 (4.3%) of TB patients were found to have FluA or FluB viral RNA
present in their sputum at the time of TB diagnosis. The TB/Flu co-infected patients
had a significantly higher bacterial load compared to those with TB mono-infection
(p = 0.0026). They had lower levels of IL17A in ex vivo sputum (p = 0.0275)
and higher MCP-1 (CCL2) levels in the blood following PPD stimulation (p =
0.0267). TB/Flu co-infected subjects had significantly higher IFN-γ+IL-17+CD4+ and
IFN-γ+IL-17-CD8+ cells compared to TB mono-infected subjects.
Conclusions: These data show that Flu co-infection at time of TB diagnosis is
associated with a higher bacterial load and differential cellular and soluble profiles. These
findings show for the first time the impact of TB/Flu co-infection in a human cohort and
support the potential benefit of Flu vaccination in TB-endemic settings.
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INTRODUCTION
Tuberculosis (TB) and influenza are two of the greatest threats to global health (1)
Recent data has indicated a role for TB in characterizing the age-specific risk of death
during the 1918–1919 Spanish influenza (H1N1) outbreak (2) while in the 2009 H1N1
pandemic, 10% of patients who died in a South African cohort also had active TB (3)
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Interestingly, while prior infection with influenza undoubtedly
increases susceptibility to secondary bacterial infections, it has
also been suggested that a reduction in immunity associated
with Mtb infection increases susceptibility to Influenza (4)
A more recent study from South Africa indicated that co-
infection with influenza is associated with an increased risk of
death compared to those hospitalized with TB mono-infection
(5) However, these observational studies have not provided
mechanistic insights.
Mtb is inhaled through air droplets to reside within
macrophages and neutrophils in the lung (6) Active TB disease
is characterized by a Type I IFN response, which modulates
the protective effects of IFN-γ by increasing production of IL-
10 and reducing downstream mediators induced by vitamin
D (7) Alveolar macrophages are also the prime target for
Influenza virus infection (8), causing their depletion and thus
loss of the first line of defense against Mtb infection. Increased
production of Type I interferons (IFNα/β) as part of the
anti-viral response inhibits the downstream effects of Type II
interferon (IFN-γ) responses known to be critical forMtb control
(9) IFNα/β-mediated signaling can promote the production
of high levels of IL-10, leading to reduction in macrophage
function (10), as well as the induction of pro-apoptotic
factors such as TRAIL resulting in loss of epithelial cells (11)
Experimental animal models have shown that influenza infection
significantly enhances susceptibility to secondary infection with
bacterial species, culminating in increased bacterial loads and
reduced survival in co-infected animals (12) Recent data has
shown that Influenza vaccination can reduce the incidence
of TB (13) and this may be mediated through Th17 cells
(14).
Despite these findings, there is a lack of understanding
of the underlying immunological mechanisms of TB/Flu co-
infections in humans. Thus, this study aimed to determine how
TB/Flu co-infection influences immunity to Mtb antigens by
determining the impact of Flu co-infection on mycobacterial
burden, lung inflammatory profiles and Mtb-specific immunity
in TB patients using multiparameter flow cytometry and luminex
profiling.
METHODS
Ethics Statement
This study was carried out in accordance with the
recommendations of MRC/Gambian Government joint
ethics committee with written informed consent from all
subjects where blood samples were taken. Samples for routine
diagnostic evaluation, including multi-pathogens, do not require
written informed consent. The protocol was approved by the
MRC/Gambian Government joint ethics committee (SCC 1333).
Subjects and Samples
Two hundred and eighty-two sputum samples used in this
study were obtained during routine diagnostic evaluation and
confirmed to be MTB complex by smear and/or liquid sputum
culture. An aliquot of sputum was digested with an equal volume
of Sputolysin (MerckMillipore, USA) for 15min and centrifuged.
The supernatant was harvested and the pellet resuspended in
Trizol (ThermoFisher, UK) and stored at −80◦C until use. For
subjects subsequently recruited to a research study, a heparinised
blood sample was also collected following written informed
consent.
Whole Blood Antigen Stimulation
Four hundred and fifty microliter whole blood was incubated
with 50µl of: phosphate buffered saline (PBS) as negative control
(NIL);or with 50 µl of phytohaemagglutinin (PHA; 5µg/ml)
as positive control; purified protein derivative (PPD; final
concentration 10µg/ml; Staten Serum Institute, Denmark) or
early secretory antigenic target 6, culture filtrate protein 10 fusion
protein (ESAT-6/CFP10; EC; final concentration 10µg/ml;
kindly provided by Prof. THM Ottenhoff, Leiden University
Medical Center (LUMC), The Netherlands). Following overnight
incubation at 37◦C, 5% CO2, supernatant was collected and
stored at−80◦C prior to use.
Multiplex Cytokine Arrays
Multiplex immunoassays were carried out using the 27-plex Bio-
Plex Pro
TM
Human Th1/Th2 Cytokine Panel (Bio-Rad, Belgium)
according to the manufacturer’s instructions. Analytes measured
were IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-
10, IL12p70, IL-13, IL-15, IL-17A, eotaxin, basic FGF, G-CSF,
GM-CSF, IFN-γ, IP-1O, MCP-1, MIP-1α, MIP-1β, PDGF-BB,
RANTES, TNF-α, and VEGF. Briefly, lyophilized standards were
reconstituted and serial dilutions performed. Coupled beads were
diluted in assay buffer and 50 µl added to each well of the
assay plate. Fifty microliter of diluted standards, blanks, samples
(stimulated whole blood supernatants or ex vivo sputum) and
controls were added per well. Plates were then incubated at
room temperature (RT), with shaking at 350 rpm, for 30min
followed by 3 washes in wash buffer. Detection antibodies were
diluted to 1 in 20 of their original concentration in detection
antibody diluent and 25 µl added to each well followed by
another 30min incubation. Following 3 washes, streptavidin-
PE was diluted to 1 in 100 in assay buffer and 50 µl added to
each well. Plates were then incubated for 10min and washed
3 times. One hundred and twenty-five microliter assay buffer
was then added to each well, plates were briefly shaken and
subsequently read using Magpix plate reader, with Bio-Plex
Manager Software (version 6.1; Bio-Rad, Belgium). No significant
differences were observed in background levels within or between
groups. Thus, all cytokine responses for NIL stimulated samples
were subtracted from those for blood incubated with EC and PPD
antigens.
Molecular Bacterial Load Assay
Preparation of Mtb Standards
Five hundred microliters of wild-type Mtb (H37Rv) stock and
800µl of mycobacteria growth indicator tube (MGIT) growth
supplement were added to a MGIT tube and incubated in a
BACTEC MGIT 960 (Becton Dickenson, USA) machine for 5
days. Viability was confirmed via a fluorescent reaction in the
MGIT tube. The tube was mixed by hand, and 500 µl was
inoculated into 20 µl 7H9 with TWEEN and incubated at 37◦C.
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Optical density (OD) was measured using a spectrophotometer
every 2 days to estimate the growth of the bacteria in conjunction
with the McFarlane scale. Once an OD of 2.2 was reached 1ml
aliquots of the suspension were frozen at −80◦C in Trizol. To
confirm the top standard concentration, 10-fold serial dilutions
of 10−1 to 10−5 were performed with 7H9 media on one aliquot.
Three 20 µl drops were plated onto 7H11 agar and incubated
at 37◦C for 3 weeks and colony forming units (CFU) were
counted.
Extraction of RNA
Before extraction, 2 µl of 560 RNA Internal Control RNA
(Bioline, UK) was spiked into 1ml sputum samples in Trizol.
Two hundred microliters of chloroform was then added to each
tube, samples were mixed vigorously and incubated at room
temperature (RT) for 10min. Samples were then centrifuged
at 13,000 rpm for 15min and the upper aqueous phase was
transferred to fresh tubes. An equal volume of 70% ethanol
(approximately 600 µl) was added to each tube and mixed
vigorously. The sample solutions were then transferred to
RNeasy MiniElute Spin Columns (Qiagen, Netherlands) and
RNA purified according to Qiagen protocol. For the standards,
RNA was extracted and 10-fold serial dilutions performed using
nuclease free water (Qiagen, The Netherlands).
Quantitative PCR
Levels of 16S RNA and internal control (IC) were quantified
using reverse transcription polymerase chain reaction (RT-
PCR). To detect 16S RNA, a master mix containing 12.5
µl Quantitect Master Mix, 6.65 µl of nuclease free water,
0.25 µl reverse transcriptase, 0.3 µl of 16S-ROX (Rox-
AGGACCACGGGATGCATGTCTTGT-BHQ2) (all supplied by
Qiagen, Netherlands) per reaction was prepared. A master mix
containing 12.5 µl Quantitect Master Mix, 5.05 µl of nuclease
free water, 0.25 µl reverse transcriptase, 1.2 µl 50 nM MgCl2+
(Qiagen, The Netherlands) and 1 µl VIC labeled 560 Control
Mix (Bioline, UK) per reaction was prepared to detect the
IC. Five microliter of RNA standards, samples or H20 were
added to the 96 well plate in triplicates; 20 µl of 16S-ROX
mastermix was added to two wells, 20 µl of IC mastermix
was added to the third. The plate was briefly vortexed, then
centrifuged at 10,000 rpm for 30s before being placed in 7500
Real-Time PCR System (Applied Biosystems, USA). The cycling
parameters were set to 50◦C for 30min, 95◦C for 10min,
then 45 cycles of 95◦C for 15 s and 60◦C for 1min. Analysis
was performed on ABI 7500 software (version 2.3, Affymetrix,
USA).
Respiratory Pathogen Multiplex qPCR
rRT-PCR was performed using a Fast Track Diagnostic (FTD)
kit (Junglister, Germany) for Influenza A (FluA) and Influenza
B (FluB). The reaction mix consisted of a primer-probe mix for
FluA/B, Fast-track 2X enzyme mix and buffer. A 25 µl total
reaction volume consisted of 10 µl RNA template or controls
(plasmid pool control and a negative RT control with water only)
and 15 µl reaction mix. The detector wavelengths used were
520 nm for FluA and 610 nm for FluB. The rRT-PCR one step
FIGURE 1 | TB/Flu co-infection significantly increases bacterial load in sputum
at diagnosis. 16S rRNA analysis was performed on sputum samples from
TB/Flu co-infected (n = 11) and TB mono-infected (n = 110) patients at
baseline. Bacterial load was calculated from a standard curve using H37Rv
reference strain. Data were analyzed using Mann-Whitney U-test. Bar
indicates median.
conditions were 42◦C for 15min, 94◦C for 3min and 40 cycles
of 94◦C for 8 s and 60◦C for 34 s. PCR was performed using
ABI QuantStudio 7-flex real-time PCR system (Thermo Fisher,
USA).
Multiparameter Flow Cytometry
Cryopreserved PBMC samples were thawed and resuspended
in RPMI+10%FCS+0.02% benzonase. After 6 h rest, cells were
counted and resuspended at 0.5–1.0 × 106 cells per test in
500 µl in polystyrene tubes and incubated at 37◦C, 5% CO2
for 16–20 h with 1X cell stimulation cocktail plus protein
transport inhibitors (CSC; eBioscience, UK), containing phorbol
12-myristate 13-acetate (PMA), ionomycin, brefeldin A and
monensin. Negative controls were incubated in the same
conditions without the PMA but with a corresponding 1X
protein transport inhibitor cocktail (PTI; eBioscience, UK). After
overnight stimulation, tubes were centrifuged at 1500 rpm for
5min and the supernatant removed. Cells were incubated with
Live/Dead Aqua (eBioscience, UK) for 10min at RT, in the
dark. Cells were washed with 1ml FACS buffer (PBS, 1% FCS,
0.2% Na Azide, 0.1% EDTA) and centrifuged at 1500 rpm
for 5min. Supernatant was removed, a cell surface cocktail of
anti-human CD3 allophycocyanin-cyanine 7 (APC-Cy7), CD8
Alexa Fluor 700 (AF700), CD161 phycoerythrin (PE), Vα7.2
allophycocyanin (APC) (all from eBioscience, UK) and CD26
fluorescein isothiocyanate (FITC) was added and incubated for
15min at 4◦C. Cells were then washed in 1ml FACS buffer and
centrifuged at 1500 rpm for 5min, 150 µl of Cytofix/Cytoperm
solution was added (Becton Dickinson, USA) and incubated
for 15min at 4◦C. Another wash step was performed and
cells were incubated with 1X Perm/Wash buffer (BD, USA) for
20min at RT, in the dark. Cells were washed and centrifuged
at 1800 rpm for 5min, supernatant removed and intracellular
cytokine staining performed with IFN-γ phycoerythrin-CF594
(PE-CF594) and IL-17 phycoerythrin-cyanine 7 (PE-Cy7) made
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FIGURE 2 | Cytokine profiles in TB/Flu Co-infection. (A) heat map showing differences in 27 cytokines/chemokines in sputum (n = 11 co-infected and n = 135
mono-infected) and antigen-stimulated blood (n = 6 co-infected and n = 80 mono-infected) from TB/Flu co-infected (A) and TB-mono-infected (B) patients. (B)
MCP-1 levels in whole blood PPD-stimulated supernatants and (C) IL-17 levels in ex vivo sputum (both pg/ml). Data were analyzed using Mann-Whitney U-test; bar
indicates median.
up in 1X Perm/Wash buffer (all from BD, USA). Cells were
incubated for 30min at RT, in the dark, washed once and
resuspended in 300 µl FACS buffer. 200,000 lymphocytes were
acquired per sample using a LSR III Fortessa flow cytometer
(BD Biosciences, USA) and BD FACSDiva software. Resultant
FACS plots were analyzed using FlowJo (Version 10.1; Treestar,
USA).
Statistics
A Mann-Whitney U test was used to compare bacterial load,
cytokine profiles and flow cytometry cell subsets in TB/Flu and
TB patients. All statistical analysis was carried out with GraphPad
Prism v7.0 (Software MacKiev, USA).
RESULTS
Participant Information
We analyzed sputum from 282TB cases and found 12 (4.3%)
were co-infected with FluA/B at the time of presentation
to the TB clinic at MRCG. Of these, 75% were FluA and
25% FluB with 50% of subjects presenting in September
(i.e., the rainy season). While the majority of samples
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were obtained for diagnostic/screening purposes with no
corresponding demographic data available, 86 patients were
subsequently enrolled in our research studies and thus had
demographic information available. No differences in age or
sex were seen between the groups with a median age of 31
[Interquartile range (IQR) 22–45] for co-infected subjects (n
= 6) and 28 [21–38] for mono-infected subjects. There were
more males than females in both groups, which is common
in The Gambia for TB patients. Known HIV-positive subjects
were excluded from the study. All patients weremicrobiologically
cured by 6 months but were not followed longer than this
to determine morbidity/mortality rates or relapse/re-infection
rates.
Out of 37 non-TB (ie patients with other respiratory diseases)
analyzed, only 1 was infected with influenza and were thus not
included in downstream analyses. They were also significantly
older than the TB mono or co-infected groups (76 years). We
performed some pilot analysis of the ORD group and did not
find any Flu associated with other infections including bacterial
pneumonia, althoughwe did see some co-infection of pneumonia
with TB. However, numbers were too small (n = 20) for any
conclusions to be drawn.
TB/Flu Co-infection Is Associated With a
Higher Bacterial Load at Diagnosis
We used 16S rRNA mycobacterial load assay to determine
viable bacilli counts in sputum samples of TB/Flu co-infected
subjects as recently published by our laboratory (15) We saw
a significant increase in bacterial load in TB/Flu co-infected
patients compared to those with TB mono-infection (median
[Interquartile range (IQR)] 2.5E5 [0.9E5-16E5] cfu/ml for co-
infected compared to 0.5E5 [0.1E5-2E5]; p= 0.0026; Figure 1).
TB/Flu Co-infection Influences Cytokine Levels in
Ex vivo sputum and Mtb-antigen Stimulated Blood
We next analyzed cytokine/chemokines in antigen-stimulated
whole blood and ex vivo sputum from subjects who also had
a paired blood sample available. In general, unstimulated (ex
vivo) sputum had higher levels of most cytokines compared
to blood stimulated overnight with EC or PPD (Figure 2A).
EC and PPD stimulated blood showed higher levels of IFN-
γ, IP-10 and MCP1 compared to sputum and NIL samples
(Figure 2A). MCP-1 levels were significantly higher in TB/Flu co-
infected compared to TB mono-infected subjects following PPD
stimulation (p = 0.0267; Figure 2B). We also saw a significantly
lower level of IL-17A in ex vivo sputum from TB/Flu co-
infected compared to TB mono-infected patients (p = 0.0275;
Figure 2C).
TB/Flu Co-infection Influences Immune Cell Subsets
When cryopreserved PBMC were analyzed by flow cytometry,
we saw a significant increase in the proportion of CD4+ T
cells simultaneously producing IFN-γ and IL17 (p = 0.0081)
and CD8+ T cells producing IFN-γ alone (p = 0.0162)
following overnight stimulation with PMA/Ionomycin in TB/Flu
compared to TB only patients (Figures 3A,B). In addition,
TB/Flu co-infected subjects had a significantly higher proportion
FIGURE 3 | Increased cellular cytokines in TB/Flu co-infection. IFN-γ and
IL-17 production from (A) CD4+ and (B) CD8+ T cells following PMA
stimulation. On the left are representative flow cytometry plots showing IFN-γ
(y-axis) and IL-17 (x-axis). Top is TB mono-infected and bottom is TB-Flu
co-infection. The graphs on the right show grouped analysis. Data were
analyzed using Mann-Whitney U-test. Bar indicates median.
of CD4+Vα7.2+CD161+ and CD8+Vα7.2+CD161++
(MAIT) cells compared to TB mono-infected subjects (p
= 0.0020 and p = 0.0283 respectively; Figures 4A–D).
When functionality of each population was assessed, we
saw significantly higher levels of CD4+Vα7.2+ cells producing
both IFN-γ and IL-17 and those producing IFN-γ alone in
TB-Flu co-infected subjects compared to TB mono-infected
subjects (p = 0.0061 and p = 0.0020 respectively; Figures 4E,G).
Similarly, TB/Flu co-infected subjects had significantly higher
proportion of CD8+ MAIT cells producing IL-17 alone (p =
0.0061; Figure 4F) but no difference in IFN-γ positive subsets
(Figure 4H).
DISCUSSION
To our knowledge, this is the first study in humans to determine
differences in immunity in patients co-infected with TB and
Influenza A/B compared to those with TB mono-infection at
diagnosis. At presentation, 4.2% of our TB patients were co-
infected with FluA/B. The TB/Flu co-infection rates are 80%
higher than those reported in a recent study from South
Africa showing an increased relative risk of death for TB/Flu
co-infection compared to TB mono-infection (5) suggesting
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FIGURE 4 | Cytokine production from MAIT cells. (A,B) Representative FACS plots showing CD4+CD161+Va7.2+ (A) and CD8+CD161+Va7.2+ (B) cells. (C,D)
total CD4+ and CD8+ MAIT cells. (E,F) IL-17+ MAIT cells and (G,H) IFN-γ+ MAIT cells. Data were analyzed using Mann-Whitney U-test. Bar indicates median. Black
dots = TB mono-infected subjects; white dots = TB/Flu co-infected subjects.
that Flu co-infection could be a major contributor to TB-
related morbidity/mortality in our setting. We found an increase
in both cellular and soluble cytokine profiles in co-infected
subjects consistent with a pro-inflammatory response. Co-
infected subjects also had increased bacterial load at the time
of diagnosis suggesting a link between pro-inflammation and
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development of disease pathology. Future studies will aim to
analyse this at the site of infection in TB patients and also to
correlate with other clinical parameters such as chest x-ray score
and spirometry.
We found a significant increase in MCP-1 (C-C Motif
Chemokine Ligand 2 (CCL2), a key chemokine that regulates
migration and infiltration of monocytes/macrophages to the
site of infection) in TB/Flu co-infected compared to TB only
patients following overnight stimulation of whole blood with
PPD. Interestingly high CCL2 levels have also been linked
with disease severity of TB patients (16) Innate immunity
is a key signature in our cohort, with an increase in both
phenotypic and functional (cytokine producing) CD4+ and
CD8+ semi-invariant Vα7.2+CD161+ cells in TB/Flu co-
infection. For CD8+ MAIT cells, this was mainly limited to
IL-17 production, while total CD8+ T cells had significantly
higher levels of IFN-γ+IL17- producing cells compared to
TB mono-infected patients. Conversely, semi-invariant CD4+
cells (likely Germline-encoded mycosyl (GEM) cells) had
significantly higher levels of IFN-γ+IL-17+ dual-producing
cells and IFN-γ+IL-17- cells while total CD4+ cells had
higher levels of dual-producing cells in co-infected patients
compared to mono-infected. In a previous study of TB
patients, accumulation of cells producing both Th1/Th17
cytokines correlated with disease severity (17) Together with
the increase in bacterial load in co-infected patients, our
findings suggest that concurrent infection with Influenza reduces
anti-microbial immunity and increases disease severity in
line with murine studies (12) Future studies should address
changes following successful TB treatment to determine if anti-
microbial immunity is restored and should also include a
control group of non-TB subjects to determine the specificity
of the response. Analysis of Type I interferon would also
be important to assess the Type I/II balance in TB/Flu co-
infection.
It was interesting to observe such a high rate of TB/Flu
co-infection in our setting. Previous studies (7) have shown
a Type I IFN signature that discriminates active TB from
latent TB infection and this may therefore be reflecting some
underlying co-infections. The major limitation of our study is
the limited sample size of co-infected subjects and those with
samples available for blood analysis. The cohort was not designed
for TB/Flu as an end-point and subsequently we were limited
in how many samples could be analyzed for immunological
parameters. Future studies should be powered for TB/Flu as an
endpoint now that incidence has been determined from this
study.
In conclusion, we have clearly shown amodulation of immune
response in patients co-infected with TB and Flu at presentation.
Flu co-infection at TB diagnosis is associated with a higher
bacterial load and differential cellular and soluble immune factors
both in the lung (sputum) and blood. These findings show for
the first time the impact of TB/Flu co-infection in a human
cohort and suggest the benefit of Flu vaccination in TB-endemic
settings.
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